# Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.

> **NCT04839991** · PHASE1 · UNKNOWN · sponsor: **Crescendo Biologics Ltd.** · enrollment: 70 (estimated)

## Conditions studied

- Advanced and/or Metastatic Solid Tumours

## Interventions

- **DRUG:** CB307

## Key facts

- **NCT ID:** NCT04839991
- **Lead sponsor:** Crescendo Biologics Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-08
- **Primary completion:** 2024-07-25
- **Final completion:** 2024-09-25
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04839991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04839991, "Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04839991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*